Kidney Cancer Association Targets Research

Share Article

Henk Verheul, M.D., Ph.D. receives 2006 Young Investigator Award.

News Image
Two of these projects encourage the direct participation of patients. This gives families an opportunity to do something that will benefit others whose lives are touched by this dreadful disease. Anyone who would like to be a part of these projects can call me directly for information--at any time.

The Kidney Cancer Association (KCA) today announced the selection of Henk Verheul, M.D., Ph.D. as recipient of the 2006 ASCO Young Investigator Award funded by a grant from the KCA.

"The KCA is taking action to cure kidney cancer by continuing our expansion of collaboration on research projects," said KCA president Bill Bro. "In addition to Dr. Verheul's important work, we're also currently involved with three statistical research projects, including that of our international staging group," Bro added. "Two of these projects encourage the direct participation of patients. This gives families an opportunity to do something that will benefit others whose lives are touched by this dreadful disease. Anyone who would like to be a part of these projects can call me directly for information--at any time."

Dr. Verheul is affiliated with Johns Hopkins School of Medicine. His project is titled "Combination antiangiogenisis and anticoagulatory therapy in patients with advanced renal cell cancer."

According to 2006 American Cancer Society statistics, 38,890 Americans will be affected by cancers of the kidney and renal pelvis this year. Nearly 13,000 will die from these diseases.

An awards presentation is planned to honor Dr. Verheul and all ASCO Foundation award recipients Sunday, June 4, 2006 at the ASCO Annual Meeting in Atlanta, Georgia. The American Society of Clinical Oncology (ASCO) is based in Alexandria, Virginia.

The KCA is a voluntary health organization, founded in 1990 by Eugene P. Schonfeld, Ph.D. and a small group of patients. The KCA educates families and physicians, serves as an advocate on behalf of patients interests, and funds research. It serves more than 72,000 constituents in 102 nations from offices in suburban Chicago. Its mission is the elimination of death and suffering from renal cancers.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Celeste Kelley
Visit website